 |
 |
I wonder if the 7 cc's means anything. was surprised I got a reply though . -----Original Message----- From: A Phillips Sent: Tuesday, October 27, 2015 7:00 AM To: [log in to unmask] Subject: Re: Ray response to Novartis looks like you're being heard ok ! > Date: Mon, 26 Oct 2015 23:33:16 -0700 > From: [log in to unmask] > Subject: Ray response to Novartis > To: [log in to unmask] > > Ms. Valenze: > > Thank you for your speedy response to my email. > > My inquiry, however, was mainly about the cost of this cancer drug and I > understood that Novartis had a “compassionate”policy for a leukemia > patient who couldn’t afford the drug. > > Dr. Brian Druker, who developed the drug informed me that the > Leukemia and Lymphoma Society paid for his research. Since Novartis > didn’t develop this drug, I was wondering how such an outrageous price of > S120,000 a year could be justified. > > I understand Georgetown University Medical Center is planning on > conducting further trials using Nilotinib for other neurodegenerative > diseases such as Alzheimer’s, ALS, and Huntington’s. > > If Tasigna or Nilotinib does prove beneficial or even curative to > Parkinson’s and/or other diseases, there is a billion dollar market for > Novartis at S1 per pill. > > Why not be truly compassionate and lower the cost of this drug? > > How heartbreaking it would be if unaffordable cures were available and > millions had to beg for them. > > Thanks again for your kind consideration of my plea. > > > From: Valenze, Virginia > Sent: Monday, October 26, 2015 12:21 PM > To: [log in to unmask] > Cc: Ericksen, Veronica ; SANDERSON, Ayo ; Frable, Anna ; JaffeNagler, > Alissa > Subject: Your Query Regarding Nilotinib Study > > Dear Ms. Brown, > > > > Thanks so much for your inquiry regarding the study on Parkinson’s > Disease. > > > > We understand that the cost of medicines can be challenging for some > patients. Novartis offers a significant patient > > Ray > Rayilyn Brown > Past Director AZNPF > Arizona Chapter National Parkinson Foundation > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: > mailto:[log in to unmask] > In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn